All Stories

  1. Highly functional duodenal stent with photosensitizers enables photodynamic therapy for metabolic syndrome treatment: Feasibility and safety study in a porcine model
  2. A novel lumen-apposing metal stent with an anti-reflux valve for endoscopic ultrasound-guided drainage of pseudocysts and walled-off necrosis: A pilot study
  3. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy
  4. Intramuscular diclofenac for the prevention of post-ERCP pancreatitis: a randomized trial
  5. Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer
  6. Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis
  7. Sa1381 The Association of Visceral Obesity and Poor Prognosis in Pancreatic Cancer
  8. Tu1948 Efficacy of Adjuvant Chemotherapy and Prognostic Factors for Patients With Extrahepatic Cholangiocarcinoma
  9. Su1721 Randomized Controlled Study for Analyzing Clinical Benefit of Pain Focused Sedation With Combination of Fentanyl and Propofol During Endoscopic Retrograde Cholangiopancreatography (ERCP)
  10. The Efficacy of Endoscopic Palliation of Obstructive Jaundice in Hepatocellular Carcinoma
  11. Clinicopathologic Characteristics Associated with Complications and Long-Term Outcomes of Endoscopic Papillectomy for Adenoma
  12. Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
  13. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer
  14. Risk factors for second primary pancreatic cancer in colorectal cancer patients
  15. Prognostic significance of quality of life in pancreatic cancer
  16. Phase II clinical trial to evaluate the efficacy and safety of activated T-lymphocyte cell therapy in gemcitabine refractory advanced pancreatic cancer
  17. Comparison of therapeutic efficacy between full-dose gemcitabine-based concurrent chemoradiotherapy (CCRT) and 5-fluorouracil based CCRT in locally advanced pancreatic cancer
  18. High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case–control study
  19. Comparison of the Sixth and Seventh Editions of the AJCC TNM Classification for Gallbladder Cancer
  20. Clinicopathologic Features and Outcomes of Pancreatic Cysts During a 12-Year Period
  21. Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma
  22. Clinical advantages of a metal stent with an S‐shaped anti‐reflux valve in malignant biliary obstruction
  23. Clinical features and outcomes of primary hepatic neuroendocrine carcinomas
  24. Sa1574 Usefulness of Contrast Enhanced Harmonic-EUS (CEH-EUS) in the Diagnosis of Neoplastic Gallbladder Polyps
  25. Safety evaluation of self‐expanding metallic biliary stents eluting gemcitabine in a porcine model
  26. Prognostic Factors and Characteristics of Pancreatic Neuroendocrine Tumors: Single Center Experience
  27. Preoperative Serum CA 19-9 Level as a Predictive Factor for Recurrence after Curative Resection in Biliary Tract Cancer
  28. Prospective Phase II Trial of Gemcitabine in Combination with Irinotecan as First-Line Chemotherapy in Patients with Advanced Biliary Tract Cancer
  29. Remission and Relapse of Autoimmune Pancreatitis
  30. M1966 Prognostic Factor for Locally Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy
  31. S1439: The Effect on Porcine Bile Duct With Metallic Stent Covered With a Gemcitabine-Incorporated Membrane
  32. T1534: Phase II Trial for Validating the Efficacy of Novel Metal Stent With Anti-Reflux Valve in Malignant Biliary Obstruction